Uploaded August 2026 | Updated September 2026, 1 week ago
Insilico Medicine
|
Webcast series featuring Insilico CEO, Alex Zhavoronkov, PhD.
🔇 TAP TO UNMUTE
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
